Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

EphA receptors regulate prostate cancer cell dissemination through Vav2-RhoA mediated cell-cell repulsion.

Batson J, Maccarthy-Morrogh L, Archer A, Tanton H, Nobes CD.

Biol Open. 2014 May 2;3(6):453-62. doi: 10.1242/bio.20146601.

2.

A role for the Golgi matrix protein giantin in ciliogenesis through control of the localization of dynein-2.

Asante D, Maccarthy-Morrogh L, Townley AK, Weiss MA, Katayama K, Palmer KJ, Suzuki H, Westlake CJ, Stephens DJ.

J Cell Sci. 2013 Nov 15;126(Pt 22):5189-97. doi: 10.1242/jcs.131664. Epub 2013 Sep 17.

3.

A role for Tctex-1 (DYNLT1) in controlling primary cilium length.

Palmer KJ, MacCarthy-Morrogh L, Smyllie N, Stephens DJ.

Eur J Cell Biol. 2011 Oct;90(10):865-71. doi: 10.1016/j.ejcb.2011.05.003. Epub 2011 Jun 22.

4.

Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human.

Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, Linardopoulos S, Balmain A.

Nat Genet. 2003 Aug;34(4):403-12.

PMID:
12881723
5.

Identification of a novel human BCL-X promoter and exon.

MacCarthy-Morrogh L, Wood L, Brimmell M, Johnson PW, Packham G.

Oncogene. 2000 Nov 16;19(48):5534-8.

6.

Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells.

MacCarthy-Morrogh L, Townsend PA, Purohit A, Hejaz HAM, Potter BVL, Reed MJ, Packham G.

Cancer Res. 2000 Oct 1;60(19):5441-50.

7.

Bcl-2-related proteins and cancer.

MacCarthy-Morrogh L, Mouzakiti A, Townsend P, Brimmell M, Packham G.

Biochem Soc Trans. 1999 Dec;27(6):785-9. Review. No abstract available.

PMID:
10830102
8.

The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours.

Purohit A, Hejaz HA, Walden L, MacCarthy-Morrogh L, Packham G, Potter BV, Reed MJ.

Int J Cancer. 2000 Feb 15;85(4):584-9.

9.

Absence of expression of the Wiskott-Aldrich syndrome protein in peripheral blood cells of Wiskott-Aldrich syndrome patients.

MacCarthy-Morrogh L, Gaspar HB, Wang YC, Katz F, Thompson L, Layton M, Jones AM, Kinnon C.

Clin Immunol Immunopathol. 1998 Jul;88(1):22-7.

PMID:
9683546
10.

The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways.

Kinnon C, Cory GO, MacCarthy-Morrogh L, Banin S, Gout I, Lovering RC, Brickell PM.

Biochem Soc Trans. 1997 May;25(2):648-50. Review. No abstract available.

PMID:
9191173
11.

Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways.

Cory GO, MacCarthy-Morrogh L, Banin S, Gout I, Brickell PM, Levinsky RJ, Kinnon C, Lovering RC.

J Immunol. 1996 Nov 1;157(9):3791-5.

PMID:
8892607
12.

The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase.

Cory GO, Lovering RC, Hinshelwood S, MacCarthy-Morrogh L, Levinsky RJ, Kinnon C.

J Exp Med. 1995 Aug 1;182(2):611-5.

13.

Discrimination between major histocompatibility complex class II DQ and DR locus products in cattle.

Dutia BM, MacCarthy-Morrogh L, Glass EJ, Knowles G, Spooner RL, Hopkins J.

Anim Genet. 1995 Apr;26(2):111-4.

PMID:
7733491
14.

Improved discrimination of bovine class II DR beta-chains polymorphisms using immunoblotting.

Knowles G, Dutia BM, Glass EJ, MacCarthy-Morrogh L, Spooner RL, Hopkins J.

Anim Genet. 1994 Jun;25(3):129-31.

PMID:
7943945

Supplemental Content

Loading ...
Support Center